<DOC>
	<DOC>NCT02079519</DOC>
	<brief_summary>This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, 1975 years of age Multiple myeloma. Progressive disease after at least 2 lines of prior therapy. Nonsecretory myeloma. History of malignancy, other than squamous cell cancer, basal cell cancer, or cancer in situ of the cervix within the last 5 years. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start. Clinically significant cardiac disease.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>